| Q43166528 | Beneficial effects of vitamin E isomer supplementation on static and dynamic bone histomorphometry parameters in normal male rats |
| Q35108973 | Biochemical markers of bone remodeling |
| Q37322534 | Bone mineral density in a cohort of adolescents during use of norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives and after discontinuation of norethisterone enanthate |
| Q41570299 | Calcium and osteoporosis |
| Q33579316 | Current and potential future drug treatments for osteoporosis |
| Q51594020 | Effect of two different progestins (cyproterone acetate and norgestrel), administered in a cyclical estradiol valerate regimen, on markers of bone turnover. |
| Q43622772 | Effects of the selective oestrogen receptor modulator-raloxifene-on calcium and PTH secretory dynamics in women with osteoporosis |
| Q34481256 | Estradiol and norgestimate: a review of their combined use as hormone replacement therapy in postmenopausal women |
| Q37151639 | High circulating estrogens and selective expression of ERβ in prostate tumors of Americans: implications for racial disparity of prostate cancer |
| Q41550777 | Hormone replacement and the menopause: a European position paper. Writing Group on Women's Health of the Fondazione Giovanni Lorenzini Medical Science Foundation |
| Q39467095 | Hormone replacement therapy in the aged. A state of the art review |
| Q33631079 | Inhibition of the progesterone nuclear receptor during the bone linear growth phase increases peak bone mass in female mice |
| Q41664444 | Menopause and post-menopause |
| Q41736037 | The calcium controversy. |
| Q38887127 | The synthetic progestin, gestodene, affects functional biomarkers in neonatal rat osteoblasts through an estrogen receptor-related mechanism of action |
| Q71510392 | Transdermal estroprogestins versus transdermal estrogen plus oral dihydrogesterone replacement in menopause |
| Q36278087 | Virgin coconut oil supplementation prevents bone loss in osteoporosis rat model |